Results 171 to 180 of about 11,283,677 (180)

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

, 2017
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, E. Jacobsen, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, J. Wiezorek, W. Go   +19 more
semanticscholar   +1 more source

Pottery from the cemetery in el-Zuma (2007 season)

2007
openaire   +1 more source

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

, 2018
F. Locke, A. Ghobadi, C. Jacobson, E. Jacobsen, D. Miklos, L. Lekakis, I. Braunschweig, O. Oluwole, Yi Lin, T. Siddiqi, A. Deol, P. Reagan, U. Farooq, A. Bot, Yi-zhou Jiang, J. Rossi, A. Xue, W. Go, S. Neelapu   +18 more
semanticscholar   +1 more source

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

, 2018
F. Locke, A. Ghobadi, L. Lekakis, D. Miklos, C. Jacobson, E. Jacobsen, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, P. Reagan, U. Farooq, A. Deol, A. Bot, J. Rossi, Yi-zhou Jiang, A. Xue, W. Go, S. Neelapu   +18 more
semanticscholar   +1 more source

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).

, 2016
S. Neelapu, F. Locke, N. Bartlett, T. Siddiqi, J. Chavez, C. Hosing, A. Cashen, L. Budde, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, J. Wiezorek, W. Go   +15 more
semanticscholar   +1 more source

Remarks on a survey of the tumuli field at el-Zuma

2004
openaire   +1 more source

Animal bone remains from the cemetery in el-Zuma (2007 season)

2007
openaire   +1 more source

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

, 2017
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, P. Reagan, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, M. Crump, J. Kuruvilla, E. Neste, U. Farooq, L. Navale, W. Go, J. Wiezorek, C. Gisselbrecht   +18 more
semanticscholar   +1 more source

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).

, 2017
J. Galon, J. Rossi, Sarah Turcan, C. Danan, F. Locke, S. Neelapu, D. Miklos, N. Bartlett, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Reagan, L. Lekakis, Sherry Unabia, W. Go, J. Wiezorek, A. Bot   +19 more
semanticscholar   +1 more source

Abstract CT135: Updated phase I results from ZUMA-1: a phase I-II multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL)

, 2016
A. Ghobadi, F. Locke, S. Neelapu, T. Siddiqi, J. Chavez, C. Hosing, N. Bartlett, L. Budde, A. Bot, J. Rossi, M. Sherman, L. Navale, M. Elias, J. Wiezorek, W. Go   +14 more
semanticscholar   +1 more source